The Antiglaucoma Drugs Global Market Report 2020-30 by The Business Research Company describes and explains the global antiglaucoma market and covers 2015 to 2020, termed the historic period, and 2020 to 2025, termed the forecast period, along with further forecasts for the period 2025-2030. The report evaluates the market across each region and for the major economies within each region.
The Antiglaucoma Drugs Global Market Opportunities And Strategies Report covers antiglaucoma drugs market drivers, antiglaucoma drugs market trends, antiglaucoma drugs market segments, antiglaucoma drugs market growth rate, antiglaucoma drugs market major players, and antiglaucoma drugs market size.
View Complete Report:
https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-market
The antiglaucoma market report focuses particularly on identifying the trends, opportunities, and strategies that can lead to success. O&S reports are available off the shelf and can be delivered to clients on the day of purchase.
Antiglaucoma Drugs Global Market Opportunities And Strategies Report is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market. The chapter also covers markets which have been positively affected by the pandemic.
Request For The Sample Now:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3522&type=smp
Trends In The Market Include:
Rho-Kinase Inhibitors In Glaucoma Treatment-
Drug manufacturers are developing new class of compounds called Rho-kinase inhibitors for the treatment of glaucoma. Rho-kinase pathway is an integral part of cellular functions such as contraction of vascular smooth muscle cells, organization of the actin cytoskeleton, cell adhesion and motility and gene expression. Rho-kinase inhibitors are different from widely used prostaglandin analogs because they target the outflow through trabecular meshwork rather than the uveoscleral outflow. Rho-kinase inhibitors have proved to decrease intraocular pressure by 25% to 30% with duration of action of 10 to 12 hours, which is more effective than the previous generation of drugs for this condition. Ripasudil hydrochloride hydrate in the form of eye drops is approved in Japan for the treatment of glaucoma and ocular hypertension. Netarsudil formulated as an ophthalmic solution is used to treat intraocular pressure in patients with open-angle glaucoma.
Development Of Combination Therapies-
Development of combination therapies for the treatment of eye related diseases including glaucoma is an emerging trend in the anti-glaucoma drugs market. Combination therapy involves the use of more than one medication or drug to treat a disease. These combinational therapies reduce the frequency of eye drops or drug administration, and reduce the possibility of vascular endothelial growth factor (VEGF) expression, choroidal neovascularization and inflammation. For instance, companies such as Allergan, Akorn and Alcon provide commercially available combination drop therapies with dosing frequency of twice or thrice daily. Similarly, companies such as Ocular Science and Imprimis Pharmaceuticals offer formulations that combine two, three, or four eye drops, thus reducing the burden and load typically associated with daily use of multiple drops.
The market is segmented:
By Product Type –
a. Alpha Agonist
b. Beta Blockers
c. Prostaglandin Analogs
d. Combined Medication
e. Others
By Disease Condition Type-
a. Open-Angle Glaucoma
b. Angle-Closure Glaucoma
c. Normal-Tension Glaucoma
d. Congenital Glaucoma
e. Other Types Of Glaucoma
By Prescription Type –
a. OTC Drugs
b. Prescription Drugs
About The Business Research Company:
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology. It has offices in the UK, the US and India and a network of trained researchers in 20+ countries globally.
Contact Information:
The Business Research Company
https://www.thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Blog: http://blog.tbrc.info/
